Antithrombin III

DRUG13 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Genzyme Corp., Instituto Grifols, S.A., University of Bari, The Hospital for Sick Children

Conditions

Acquired Antithrombin III DeficiencyAcute Coronary SyndromeAcute LeukemiaAntithrombin III DeficiencyAortic Valve InsufficiencyAortic Valve StenosisCardiopulmonary BypassCirrhosis, Liver

Phase 1

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

TerminatedNCT01698567

University of RochesterCongenital Heart Disease

Start: 2012-07-31End: 2016-03-31Updated: 2016-03-22

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

CompletedNCT02631174

Children's Hospital Medical Center, CincinnatiCardiopulmonary Bypass, Extracorporeal Membrane Oxygenation Complication

Start: 2015-06-30End: 2018-06-30Updated: 2019-01-25

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

WithdrawnNCT04055389

Jonathan StineCirrhosis, Liver, Portal Vein Thrombosis

Start: 2021-01-01End: 2022-02-22Updated: 2022-03-10

Phase 2

Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

CompletedNCT00823082

Instituto Grifols, S.A.Acquired Antithrombin III Deficiency, Coronary Artery Bypass

Start: 2009-06-30End: 2011-09-30Updated: 2016-09-20

Antithrombin III in Infectious Disease Caused by COVID-19

TerminatedNCT04899232

Enrique GinzburgAntithrombin III Deficiency, Covid19

Start: 2021-07-06End: 2022-03-31Updated: 2022-09-07

Phase 3

Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

CompletedNCT01530737

The Hospital for Sick ChildrenCardiopulmonary Bypass

Start: 2011-11-30End: 2014-10-31Updated: 2015-01-07

A Phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B with or without inhibitory antibodies to factor VIII or IX

Active, not recruitingCTIS2022-500221-33-01

Sanofi-Aventis Recherche & DeveloppementHemophilia

Start: 2023-07-28Target: 17Updated: 2025-08-29

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

CompletedCTIS2023-508884-59-00

Genzyme Corp.Hemophilia A or Hemophilia B

Start: 2024-06-03End: 2025-11-17Target: 18Updated: 2025-08-21

Phase 4

Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery

University of BariAcute Coronary Syndrome, Aortic Valve Insufficiency, Aortic Valve Stenosis +2

Start: 2009-09-30End: 2011-11-30Target: 90Updated: 2010-09-15

Unknown Phase

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

CompletedNCT04651400

OctapharmaCovid19

Start: 2020-10-19End: 2022-09-27Updated: 2023-10-10

Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO

CompletedNCT04879550

Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research HospitalAntithrombin III Deficiency, Extracorporeal Membrane Oxygenation Complication

Start: 2020-01-01End: 2022-03-01Updated: 2022-05-24

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

CompletedNCT04912193

Asan Medical CenterLiver Transplantation and Antithrombin

Start: 2010-01-04End: 2019-12-31Updated: 2021-06-03

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

CompletedNCT07036809

Muhamed Ahmed Abdelmoaty Muhamed AlhagrasyAcute Leukemia

Start: 2023-06-01End: 2025-10-01Updated: 2026-01-29

Related Papers

A novel description of AT deficiency in hospitalized COVID-19 patients.

PubMed2025-01-01